Skip to Content
Merck
  • Spectrum of glutamate dehydrogenase mutations in Japanese patients with congenital hyperinsulinism and hyperammonemia syndrome.

Spectrum of glutamate dehydrogenase mutations in Japanese patients with congenital hyperinsulinism and hyperammonemia syndrome.

Osaka city medical journal (2011-11-24)
Kazuyoshi Aso, Yoshiyuki Okano, Taisuke Takeda, Osamu Sakamoto, Kyoko Ban, Kazumi Iida, Tsunekazu Yamano, Haruo Shintaku
ABSTRACT

Congenital hyperinsulinism and hyperammonemia (CHH) is caused by gain of function of glutamate dehydrogenase (GDH). The genetic abnormalities are known to be located in three specific regions on the GDH protein. We describe here three different missense mutations identified in five new Japanese patients with CHH. And to study the genotype-phenotype correlations in patients with GLUD1 mutations, we analyzed previously reported Japanese cases. An Epstein-Barr virus-transformed lymphoblastoid cell line was established from the 5 patients and control subjects, and was used for enzymatic and molecular analyses. All patients developed seizures with loss of consciousness associated with hypoglycemia and had persistent hyperammonemia. All patients had similar basal GDH activity of lymphoblasts and insensitivity to GTP inhibition. Genetic studies identified heterozygous I444M mutation in Patient 11, S217C mutation in Patient 1, and H262Y mutation in Patients 2, 3, and 4. Patients 3 and 4 were child and father, respectively. COS cell expression study confirmed that I444M and H262Y mutations were disease-causing genes. We identified three mutations (I444M, H262Y, and S217C), and the former is a newly described mutation. A summary of 17 reported Japanese patients (10 boys and 7 girls) with GDH mutations showed 8 patients had mutation at the site of the GTP-binding region, 2 at the site of the antenna-like structure, and 7 at the site of the hinge region. Analysis of the reported cases showed no clear association between clinical phenotype and mutation sites. However, G446D mutation seems to be associated with serious abnormalities.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Glutamic Dehydrogenase from bovine liver, Type III, lyophilized powder, ≥20 units/mg protein
Sigma-Aldrich
L-Glutamic Dehydrogenase from bovine liver, Type II, 50% glycerol solution, ≥35 units/mg protein
Sigma-Aldrich
L-Glutamic Dehydrogenase from bovine liver, Type I, ammonium sulfate suspension, ≥40 units/mg protein